摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[4-[(3-Methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]-2-propoxypropanoic acid

中文名称
——
中文别名
——
英文名称
3-[4-[(3-Methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]-2-propoxypropanoic acid
英文别名
——
3-[4-[(3-Methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]-2-propoxypropanoic acid化学式
CAS
——
化学式
C22H24N2O5
mdl
——
分子量
396.4
InChiKey
NTFUOTRUFHBSCW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    29
  • 可旋转键数:
    9
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    88.4
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE
    申请人:LOHRAY Braj Bhushan
    公开号:US20080188402A1
    公开(公告)日:2008-08-07
    The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. This invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine.
    本发明涉及新的取代吡咯化合物、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组成物。本发明特别涉及一般式(I)的新的取代吡咯化合物、它们的类似物、衍生物、多晶形态、互变异构体、药学上可接受的盐、药学上可接受的溶剂和含有它们的药物组成物。本发明还涉及制备这种化合物的过程、含有这种化合物的组成物以及这种化合物和组成物在医学上的使用。
  • NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    申请人:Dr. Reddy's Laboratories Ltd.
    公开号:EP1073643B1
    公开(公告)日:2004-12-29
  • US7323491B2
    申请人:——
    公开号:US7323491B2
    公开(公告)日:2008-01-29
  • US8110598B2
    申请人:——
    公开号:US8110598B2
    公开(公告)日:2012-02-07
  • [EN] NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES, LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:——
    公开号:WO1999008501A2
    公开(公告)日:1999-02-25
    [EN] The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel beta -aryl- alpha -oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
    [FR] L'invention concerne de nouveaux composés anti-obésité et hypocholestérolémiques, leurs dérivés, leurs analogues, leurs formes tautomères, leurs stéréoisomères, leurs polymorphes, leurs sels acceptables sur le plan pharmaceutique, leurs solvates acceptables sur le plan pharmaceutique et des compositions acceptables sur le plan pharmaceutique les contenant. Elle concerne, plus particulièrement, de nouveaux acides beta -aryl- alpha -oxysubstitué alkylcarboxyliques représentés par la formule (I), leurs dérivés, leurs analogues, leurs formes tautomères, leurs stéréoisomères, leurs polymorphes, leurs sels acceptables sur le plan pharmaceutique, leurs solvates acceptables sur le plan pharmaceutique et des compositions acceptables sur le plan pharmaceutique les contenant. (I)
查看更多